Alprostadil: Side Effects

Safety Profile Overview#

Alprostadil (prostaglandin E1) has been in clinical use since the 1980s and has an extensively characterized safety profile based on large-scale clinical trials, decades of post-marketing surveillance, and FDA-approved prescribing information. Unlike many investigational compounds, alprostadil has undergone rigorous regulatory review for multiple indications, providing a robust adverse-event database. The side effect profile varies significantly depending on the route of administration and the clinical indication.

Side Effects by Route of Administration#

Intracavernosal Injection (Caverject/Edex)#

Intracavernosal injection is the most studied route for erectile dysfunction treatment. The adverse events are predominantly local in nature, reflecting the targeted delivery to penile tissue.

Penile pain is the most frequently reported adverse effect, occurring in approximately 30-50% of patients in clinical trials. The pain is typically described as a burning or aching sensation at the injection site or along the shaft, beginning within minutes of injection and lasting 10-60 minutes. In the pivotal Caverject trial by Linet and Ogrinc (1996), penile pain was reported by 37% of patients. Pain severity is generally mild to moderate and tends to diminish with repeated use. Proposed mechanisms include direct prostaglandin-mediated sensitization of nociceptors and local tissue distension. Management strategies include:

• Slowing the injection speed
• Warming the reconstituted solution to body temperature before injection
• Using the alpha-cyclodextrin formulation (Edex), which some patients tolerate better
• Application of topical lidocaine or EMLA cream before injection (limited evidence)
• Dose reduction to the minimum effective dose

Priapism -- defined as an erection lasting more than 4 to 6 hours -- is the most serious potential complication, occurring in approximately 1-4% of patients in clinical trials. Ischemic priapism is a urological emergency because prolonged erection leads to corporal ischemia, acidosis, and irreversible smooth muscle damage if not treated within 4-6 hours. The risk is dose-dependent and is highest during the dose-titration phase. Risk factors include higher doses, concurrent use of other vasoactive ED medications, and conditions predisposing to priapism (sickle cell disease, leukemia, multiple myeloma, polycythemia). Emergency management involves:

• Aspiration of blood from the corpora cavernosa using a large-bore needle
• Intracavernosal injection of a sympathomimetic agent (phenylephrine 100-500 mcg every 5-10 minutes, preferred over epinephrine due to lower risk of cardiac arrhythmia)
• Surgical shunting procedures if pharmacological detumescence fails

Penile fibrosis develops in approximately 2-12% of patients with long-term use (typically after 6-12 months of regular injections). This manifests as palpable fibrous plaques or nodules at injection sites, similar to Peyronie disease. In severe cases, penile curvature or difficulty with injection may occur. The incidence is related to injection frequency, injection technique, and possibly the formulation used. Prevention strategies include:

• Limiting injection frequency to a maximum of 3 times per week with at least 24 hours between injections
• Rotating injection sites within the dorsolateral corpus cavernosum
• Using proper injection technique with a fine-gauge needle (27-30 gauge)
• Regular self-examination and periodic physician examination for plaque detection
• Discontinuation of injection therapy if significant fibrosis develops

Other local effects include ecchymosis at the injection site (approximately 2-5%), hematoma (1-3%), and penile edema (1-2%). Urethral bleeding from inadvertent urethral puncture occurs rarely.

Systemic effects from intracavernosal injection are uncommon because systemic absorption of the drug is limited (approximately 2-5% of the injected dose reaches the systemic circulation). Reported systemic effects include dizziness (1-2%), headache (<1%), and flu-like symptoms (<1%).

Intraurethral Administration (MUSE)#

The MUSE (Medicated Urethral System for Erection) pellet delivers alprostadil through the urethral mucosa. Its side effect profile differs from intracavernosal injection.

Urethral pain or burning is the most common adverse effect, reported in approximately 24-36% of patients in clinical trials. This typically occurs during or shortly after pellet insertion and resolves within 30-60 minutes. The burning sensation reflects direct prostaglandin stimulation of urethral mucosal nociceptors.

Penile pain occurs in approximately 18-33% of patients, somewhat lower than with intracavernosal injection, and is generally milder in intensity.

Hypotension and dizziness are more common with MUSE than with intracavernosal injection, occurring in approximately 1-3% and 2-4% of patients, respectively. This reflects greater systemic absorption from the urethral mucosa compared to the relatively isolated corpus cavernosum during erection.

Minor urethral bleeding or spotting is reported in approximately 4-5% of patients and typically resolves without intervention. It results from minor mucosal trauma during pellet insertion.

Priapism occurs less frequently with MUSE than with intracavernosal injection (reported in fewer than 1% of patients in clinical trials), likely because of lower local drug concentrations achieved at the corporal smooth muscle.

Vaginal burning or irritation has been reported in approximately 5-10% of female partners of men using MUSE, attributed to transfer of residual alprostadil during intercourse. Use of a condom is recommended if the partner experiences discomfort.

Intravenous Administration (Prostin VR Pediatric)#

Intravenous alprostadil for neonatal PDA management has a distinct and more serious side effect profile reflecting both the systemic administration route and the vulnerability of the neonatal patient population.

Apnea is the most significant adverse effect, reported in approximately 10-12% of neonates. It typically occurs within the first hour of infusion and is more common in neonates weighing less than 2 kg at birth. The mechanism is thought to involve prostaglandin-mediated depression of central respiratory drive. Management requires:

• Continuous cardiorespiratory monitoring in a neonatal intensive care unit
• Immediate availability of intubation equipment and mechanical ventilation
• Dose reduction to the lowest effective infusion rate
• Approximately 12% of neonates receiving alprostadil require mechanical ventilation

Fever occurs in approximately 14% of neonates and reflects the thermoregulatory effects of prostaglandins on the hypothalamus. This is typically low-grade and does not require specific treatment unless associated with other signs of infection, which must be excluded.

Flushing and cutaneous vasodilation occur in 10% of neonates, reflecting the systemic vasodilatory properties.

Seizures have been reported in approximately 4% of neonates, though causal attribution to alprostadil versus the underlying congenital heart disease is difficult to establish.

Hypotension occurs in approximately 4% of neonates and is managed with infusion rate reduction and supportive care. Severe hypotension may necessitate vasopressor support.

Cortical proliferation of long bones (periosteal hyperostosis) has been observed with prolonged infusion (typically more than 120 hours). This is a reversible finding that manifests as periosteal new bone formation on radiographs. It has been reported in approximately 6-12% of neonates receiving prolonged alprostadil infusions and typically resolves after discontinuation.

Disseminated intravascular coagulation (DIC) and bleeding complications have been rarely reported, reflecting the antiplatelet effects of PGE1 in the setting of neonatal coagulopathy.

Gastric outlet obstruction due to antral mucosal proliferation has been reported with prolonged high-dose infusion, occurring in approximately 1-7% of neonates receiving alprostadil for more than 2 weeks.

Contraindications -- Detailed Discussion#

Conditions Predisposing to Priapism#

Patients with sickle cell disease or trait, multiple myeloma, leukemia, polycythemia vera, or thrombocythemia have an inherently increased risk of priapism due to hyperviscosity, abnormal blood rheology, or infiltrative processes affecting the corpora cavernosa. The addition of a potent smooth muscle relaxant such as alprostadil substantially increases this risk. These conditions represent absolute contraindications to intracavernosal and intraurethral alprostadil use.

Penile Anatomical Abnormalities#

Significant penile anatomical deformities (severe hypospadias, severe curvature, cavernosal fibrosis) can lead to unpredictable drug distribution within the corpora, increasing the risk of both treatment failure and complications such as priapism. Patients with penile implants should not receive intracavernosal injections due to risk of implant damage and infection.

Urethral Conditions (MUSE-specific)#

Active urethritis, balanitis, or urethral stricture are contraindications to intraurethral alprostadil because of the risk of exacerbating infection, increased systemic absorption through inflamed mucosa, and difficulty with pellet insertion through a narrowed urethra.

Reproductive Considerations#

MUSE labeling specifically advises against use by couples attempting to conceive, as alprostadil absorbed vaginally could potentially affect cervical anatomy or function. A condom should be used during intercourse. The intracavernosal formulations do not carry this same warning to the same degree but a condom barrier is similarly recommended.

Drug Interactions#

Anticoagulants and Antiplatelet Agents#

Alprostadil inhibits platelet aggregation through cAMP-mediated signaling in platelets. When coadministered with anticoagulants (warfarin, heparin, low-molecular-weight heparins, direct oral anticoagulants) or antiplatelet agents (aspirin, clopidogrel, prasugrel), there is a theoretical and pharmacologically plausible risk of enhanced bleeding. Clinical significance is most relevant for neonatal IV use, where the combination with heparin (used for maintaining vascular access) may contribute to bleeding complications.

Antihypertensive Medications#

The vasodilatory effects of alprostadil can potentiate the blood-pressure-lowering effects of antihypertensive medications. This interaction is most clinically relevant with:

• Alpha-adrenergic blockers (doxazosin, tamsulosin, terazosin): dual vasodilation through alpha-blockade and prostanoid-mediated relaxation
• Calcium channel blockers: additive smooth muscle relaxation
• ACE inhibitors and ARBs: combined reduction in vascular tone
• Nitrates: although the interaction is less dangerous than with PDE5 inhibitors, additive hypotension is possible

Patients should be counseled about the risk of postural hypotension, particularly with the first dose.

Other Erectile Dysfunction Agents#

Concurrent use of alprostadil with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) or other vasoactive intracavernosal agents increases the risk of both priapism and systemic hypotension. If combination therapy is being considered, it should be initiated under close medical supervision with careful dose titration.

MAO Inhibitors#

Monoamine oxidase inhibitors may theoretically potentiate the cardiovascular effects of alprostadil by reducing catecholamine metabolism, potentially exacerbating hypotension. Although clinical data on this interaction are limited, caution is advised.

Toxicology and Overdose#

Alprostadil overdose with intracavernosal injection manifests primarily as prolonged erection (priapism) and is managed as described above. Systemic overdose via the intravenous route produces severe hypotension, bradycardia, respiratory depression, and potentially apnea. There is no specific antidote; treatment is supportive with volume resuscitation, vasopressors, and airway management as needed. The extremely short half-life of alprostadil (30 seconds to 10 minutes) means that systemic effects resolve rapidly after discontinuation of infusion.

Animal toxicology studies have established median lethal doses (LD50) in mice of approximately 2.5 mg/kg IV and 186 mg/kg subcutaneously, indicating a wide margin of safety between therapeutic and lethal doses. Chronic toxicology studies in dogs and monkeys at doses up to 400 mcg/kg/day for up to 52 weeks revealed hyperostosis (excess bone formation), periosteal reactions, and gastric mucosal changes at suprapharmacological doses but no carcinogenicity.

Evidence Quality and Post-Marketing Surveillance#

The adverse event profile of alprostadil is based on a robust evidence base including:

• Phase III pivotal trials involving more than 1,600 patients for Caverject
• Phase III trials involving approximately 1,500 patients for MUSE
• Extensive neonatal clinical experience with Prostin VR since its approval in 1981
• Decades of post-marketing surveillance and pharmacovigilance reporting
• Comprehensive FDA-approved prescribing information with detailed adverse event tables

This evidence base is substantially more extensive and rigorous than that available for most investigational peptides, providing clinicians with well-characterized risk-benefit assessments for each approved indication and route of administration.

Related Reading#

• Alprostadil overview and research guide
• Alprostadil dosing protocols
• Alprostadil risks and legal status